Streetbeat News

Analyst Ratings

VCEL

Vericel (NASDAQ:VCEL) has received various analyst ratings in the last quarter, with 3 bullish, 2 somewhat bullish, and 3 indifferent. The average price target for the stock is $41.31, indicating an upside from its current price of $32.53. This average has increased by 5.92% from the previous target of $39.00.

Portfolio Pulse from Benzinga Insights

October 16, 2023 | 5:00 pm

BLK

JP Morgan has maintained its Overweight rating for BlackRock (NYSE:BLK) but lowered its price target from $736.00 to $708.00. BlackRock's shares are currently trading up 1.72% at $638.46 per share. A move to $708.00 would represent a 10.89% increase from the current share price.

Portfolio Pulse from Benzinga Insights

October 16, 2023 | 5:00 pm

JPM

BMO Capital analyst James Fotheringham has maintained a 'Market Perform' rating on JPMorgan Chase (NYSE:JPM) and raised the price target from $167 to $171.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 4:57 pm

DTE

BMO Capital analyst James Thalacker has maintained a 'Market Perform' rating on DTE Energy (NYSE:DTE) and raised the price target from $106 to $109.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 4:56 pm

C

BMO Capital analyst James Fotheringham maintains an Outperform rating on Citigroup (NYSE:C) and raises the price target from $61 to $66.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 4:54 pm

NVDA

TSLA

Cathie Wood, the founder of Ark Invest, has stated that she expects 'upside surprises' for Tesla (TSLA) to be much more than for Nvidia (NVDA).

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 4:49 pm

TSX:HLF

BMO Capital analyst Nevan Yochim has initiated coverage on High Liner Foods with a Market Perform rating and a price target of C$12.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 4:47 pm

IMVT

Cantor Fitzgerald analyst Louise Chen maintains an Overweight rating on Immunovant (NASDAQ:IMVT) and raises the price target from $30 to $45.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 4:42 pm

BMRN

Cantor Fitzgerald analyst Olivia Brayer has reiterated an Overweight rating on Biomarin Pharmaceutical (NASDAQ:BMRN) and maintained a price target of $120.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 4:39 pm

PXD

XOM

BMO Capital Markets analyst Phillip Jungwirth has downgraded Pioneer Natural Resources Co (PXD) to Market Perform from Outperform rating following its all-stock merger with Exxon Mobil Corp (XOM) for $59.5 billion. Despite the downgrade, the analyst views the deal favorably and anticipates it to close in 2Q24. PXD shares are trading higher by 0.17% at $248.65.

Portfolio Pulse from Lekha Gupta

October 16, 2023 | 4:38 pm